According to a report by Revista Forum, a 47-year-old man named Arnaldo Machado was hospitalized and forced to undergo treatment for seven months due to lung issues caused by the use of an e-cigarette. He now warns about the dangers of this device and opposes the ongoing debate in France seeking its legalization.
Machado developed a lung disease called "EVALI" after using an e-cigarette device. This disease was first described in the United States in 2019 and is associated with the use of e-cigarette devices.
His lungs have developed a fatty wall, similar to how fat in the lungs obstructs his breathing. He opposes the legalization of the product and calls on authorities to completely ban it. The aerosol produced by this device, known as e-liquid, may contain various harmful substances such as nicotine, heavy metals, and flavorings, which users may inhale.
Furthermore, the use of e-cigarettes may lead to nicotine dependence, increase the risk of adolescents initiating smoking, and potentially cause damage to the oral mucosa, resulting in throat and eye pain, rhinitis, pneumonia, and other diseases.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
